Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients: A retrospective cohort study.

Lotte M. Knapen,Rutger Koornstra,Johanna H. M. Driessen,Bas van Vlijmen,Sander Croes,Stein Schalkwijk,Angela Colbers,Winald R. Gerritsen,David M. Burger,Frank de Vries,Nielka P. van Erp

Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients: A retrospective cohort study.

2017

Lotte M. Knapen
Rutger Koornstra
Johanna H. M. Driessen
Bas van Vlijmen
Sander Croes
Stein Schalkwijk
Angela Colbers
Winald R. Gerritsen
David M. Burger
Frank de Vries
Nielka P. van Erp

9540Background: Vemurafenib is used for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. The approved fixed vemurafenib dose of 960 mg twice dai...

Keywords:

Melanoma
Pathology
Vemurafenib
Oncology
Retrospective cohort study
Concomitant
BRAF V600 Mutation
Internal medicine
Medicine
metastatic melanoma
adult patients

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations